在患有基本高血压的患者中,α-阿杜和盐敏感性的多态性
D Cusi1, C Barlassina, T Azzani
1Postgraduate School of Nephrology, University of Milan, Italy.
Lancet (London, England)
|May 10, 1997
概括
一种特定的α-阿杜基因变异 (Gly 460 Trp) 与基本高血压有关. 具有这种突变的个体表现出增加的盐敏感性和对利尿剂治疗的更好的反应.
科学领域:
- 遗传学 是一个遗传学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
背景情况:
- 脏运输中的异常与高血压有关.
- 据推测,管中的一种蛋白质 - - 素 - - 通过actin细胞骨架调节离子运输.
研究的目的:
- 为了研究一个α-阿杜素基因多态 (Gly 460 Trp) 和基本高血压之间的关联.
- 评估这种多形态对血压对平衡变化的反应的影响.
主要方法:
- 在137个高血压兄弟夫妇中,使用在α-阿杜素位点附近的DNA标记物进行链接分析.
- 477名高血压和322名正常血压个体的基因定型,以确定阿尔法-阿杜多态.
- 在有或没有460Trp等位基因的高血压患者中,对盐敏感性 (急性和慢性) 的测试.
主要成果:
- 观察到阿尔法-阿杜辛位标记物和基本高血压之间存在显著的联系.
- 在460 Trp突变和高血压之间发现了显著的关联 (p = 0.0003).
- 与野生类型同位素相比 (p = 0.001和p = 0.002,分别) 患有突变基因 (Gly/Trp) 的患者在应对变化和甲治疗时表现出更大的血压降低.
结论:
- 阿尔法-阿杜基位与基本高血压有显著的联系.
- Gly 460 Trp的多态性与一种对盐敏感的基本高血压形式有关.
- 这种多形态可能有助于识别可能受益于利尿疗法或减少的策略的高血压患者.
相关概念视频
Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...


